The postdoc position is funded by the french National Cancer Institute (INCa). It will consist in developing mechanistic models of the response to immune-checkpoint inhibitors (ICI) using large-scale (~450 patients), longitudinal and multi-modal biological data generated by the PIONeeR clinical study (RHU program).
